ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer disease medicine policy neuroscience

Alternative Medicines
The Scientist | Jul 1, 2012 | 10+ min read
As nonconventional medical treatments become increasingly mainstream, we take a look at the science behind some of the most popular.
Collage of faces
Remembering Those We Lost in 2022
Lisa Winter | Dec 26, 2022 | 5 min read
A look at some noteworthy scientists who died this year, leaving behind a legacy of research excellence.
Rewards of Risk
Megan Scudellari | Feb 1, 2011 | 7 min read
Secrets to scoring big money grants for innovative, out-of-the-box research
Artist’s rendering of brain fog: a bright blue drawing of a brain sits inside of a pink drawing of a head in profile surrounded by miscellaneous shapes
Brain Fog Caused by Long COVID and Chemo Appear Similar
Dan Robitzski | Jan 28, 2022 | 6 min read
Data from mouse models for mild coronavirus infections and human tissue samples offer further evidence that it doesn’t take a severe infection—or even infection of brain cells at all—to cause long-term neurological symptoms.
Week in Review: August 5–9
Jef Akst | Aug 9, 2013 | 5 min read
Flu researchers propose H7N9 studies; NIH makes deal to share HeLa genome; herbal “remedies” can cause cancer; scientists record grid cell activity in humans
a pipette dropping clear liquid into a well plate
California Voters to Decide Future of Stem Cell Funding Agency
Katarina Zimmer | Oct 24, 2020 | 6 min read
If approved, Proposition 14 would authorize the state to sell $5.5 billion in bonds to extend the life of CIRM, which funds stem cell research. The ballot measure has its critics.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.

Run a Search

ADVERTISEMENT